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Abstract
Background/Aim. For almost two decades extremity am-
putation has not been the only viable option for patients with
from bone cancer in the region of the hip and knee. Remark-
able advances in implant technology, surgical reconstructive
technique and adoption of new chemotherapy protocols pro-
vide a new option for surgeons who diagnose and treat bone
tumors. Megaendoprosthesis has become widely accepted al-
ternative in limb salvage surgery of the extremities. The aim of
this study was to present an outcome of the treatment of bone
tumors in the knee and hip region by the use of custom made
megaendoprothesis. Methods. In the period 2006–2008 we
adopted new clinical practice protocols for preoperative man-
agement in candidates for tumor megaprostheses of the hip
and knee including: surgical tumor staging, histopathological
verification, determinants of anatomical-mechanical defect,
status of soft tissues, CT evaluation of the referent measures
of pelvis, femur and tibia necessary for creation of custom
made endoprosthesis and surgery plan, as well as modern, less
invasive surgical approach. The patients were monitored dur-
ing ≥ 24 months after the surgery for detecting possible com-
plications. Results. All procedures were performed without
complications during and immediately after the surgery. Dur-
ing the follow-up period not less than 24 months we failed to
record any significant complications. Conclusion.  Custom
made megaendoprosthesis are the method of choice in the
treatment of bone tumors in the region of the hip and knee at
the Orthopedics and Traumatology Clinic, Military Medical
Academy, Belgrade. The greatest challenge – ensuring longev-
ity of a prosthesis can be achieved not only by prevention of
common complications of arthroplasty procedures but, cer-
tainly, with the introduction of new methods for preoperative
planning – computer-assisted technique of measuring referent
sizes and software solutions for the selection and design of
custom-made components of an endoprosthesis.
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Apstrakt
Uvod/Cilj. Već skoro dve decenije amputacija ekstremi-
teta nije jedina dostupna opcija za obolele od koštanih
tumora u regiji kuka i kolena. Izuzetan napredak u teh-
nologiji implantata, hirurškoj rekonstruktivnoj tehnici,
kao i usvajanje novih hemioterapijskih protokola obezbe-
dili su nove mogućnosti za hirurge koji dijagnostikuju i le-
če koštane tumore. Megaendoproteze su postale široko
prihvaćena alternativa u limb salvage hirurgiji ekstremiteta.
Cilj rada bio je da se prikaže način izvođenja i ishod leče-
nja koštanih tumora kolena i kuka primenom megaendop-
roteza.  Metode.  U periodu od 2006. do 2008. godine
primenjeno je osam custom made tumorskih megaendop-
roteza kuka i kolena, po protokolu koji je obuhvatao hi-
ruršku procenu agresivnosti tumora, patohistološku veri-
fikaciju, anatomsko-mehaničke odrednice defekta, status
mekih tkiva, egzaktnu CT evaluaciju referentnih veličina
karlice, femura i tibije potrebnu za izradu custom made en-
doproteze i planiranje hirurgije, kao i savremeni poštedni
hiruški pristup. Operisani bolesnici praćeni su, potom,
najmanje 24 meseca. Rezultati. Svi bolesnici bili su bez
komplikacija tokom i neposredno po operativnom za-
hvatu. Tokom perioda praćenja, ne manjeg od 24 meseca,
nisu evidentirane značajnije komplikacije kod praćenih
bolesnika.  Zaključak.  Custom made endoproteze kuka i
kolena predstavljaju metod izbora u lečenju koštanih tu-
mora u regiji kuka i kolena. Najveći izazov – obezbeđiva-
nje dugovečnosti proteze, postiže se ne samo prevencijom
uobičajenih komplikacija artroplastičnih procedura, već,
svakako, i uvođenjem novih metoda u preoperativno pla-
niranje – kompjuterski asistirane tehnike merenja refe-
rentnih veličina, i softverskih rešenja za selekciju i izradu
custom made komponenata endoproteze.
Ključne reči:
kosti, neoplazme; ortopedske procedure; kuk, proteza;
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Introduction
For almost two decades extremity amputation has not
been the only viable option for patients with bone cancer in
the region of the hip and knee. Remarkable advances in im-
plant technology, surgical reconstructive technique and
adoption of new chemotherapy protocols provides a new op-
tion for the surgeons who diagnose and treat bone tumors.
Megaendoprosthesis has become widely accepted alternative
in limb salvage surgery of the extremities. They allow resto-
ration of function, improve the control of malignant disease
and subjective patient satisfaction.
A success in limb salvage approach depends upon un-
derstanding of tumor biology and assessment of tumor ag-
gressiveness, advances in reconstructive techniques and the
development of effective chemotherapy protocols for pri-
mary and secondary bone tumors. Metal implants fixed with
polymethylmethacrylate (PMMA) cement have been recog-
nized for a long time as a successful modality of treatment of
pathological bone fractures after metastasis 
1.
In patients with disseminated metastatic disease, treat-
ment should improve the quality of life in line with progno-
sis. In these cases the demands and needs for endoprosthesis
are temporally and functionally restricted to facilitate the
mobilization and health care. On the other hand, patients
with newly diagnosed bone tumor, that requires resection,
are often young and are expected to live with the prosthesis
for many years. A substantial amount of healthy bone may
need to be resected to provide a safe margin, leaving a rem-
nant bone segment not enough to secure fixation of a
megaendoprosthesis 
1.
Reconstructive options after resection of tumors in the
region of the hip and knee, besides a custom made endo-
prosthesis, include osteoarticular alografting, alograft-
prosthesis composites, arthrodesis with intercalary bone
graft and rotational plastic procedures. However, only re-
section with grafting, arthrodesis and rotational plastic pro-
cedures such as VanNes rotational plasty has many func-
tional restrictions and can be applied only in exceptional
cases. In the Military Medical Academy, Belgrade, Clinic
for Orthopedics and Traumatology, if we chooselimb sal-
vage approach, than surgical excision of bone tumors in the
region of the hip and knee and defect reconstruction with
custom made megaendoprosthesis is the method of choice
in the treatment. Megaendoprosthesis provides numerous
advantages, one of them being the possibility that a patient,
soon, returns to daily activities with the full weight bearing.
It is very important, because the available data show that
approximately 25% of these patients live less than two
years after the surgery 
1. Other advantages are reliability,
availability, and proven favorable cost-effectiveness ratio 
2.
Nevertheless, possible complications of reconstructive sur-
gery, in general, such as infection, aseptic loosening, dislo-
cation of prosthesis, joint stiffness or contracture, instabil-
ity of components, and implant mechanical weaknesses
may compromise the outcome, and the possibility of a suc-
cessfull revision, when the only remaining option is ampu-
tational surgery 
3.
Methods
In the period 2006–2008, eight patients with primary
malignant bone tumors were treated with wide resection and
megaendoprosthetic reconstruction. Postoperative follow-up
of each patient was at least 24 months. All patients were
treated with a custom made megaendoprosthesis, a specially
designed endoprosthesis based on the exact anatomical
model of each patient. It was a moment of great significance
for the reconstruction of the large weight-bearing joints such
as the hip and knee. In our series, we did not use ready-made
solutions for reconstructive procedures in the hip and knee
region, since their lack of individualization significantly lim-
its the application for the restoration of ideal relations in the
joint. A properly restored joint biomechanics is one of the
basic durability prerequisites of all arthroplastic procedures
and tumor reconstruction, as well 
4–6.
Eight patients were treated with megaendoprosthesis:
three patients with giant cell tumors of the distal femur, two
patients with chondrosarcoma in the knee region, two pa-
tients with osteosarcoma in the region of the knee and one
patient with chondrosarcoma in the region of the hip and
pelvis. Selection of patients for this type of treatment was
carried out after extensive diagnostic evaluations of the Sar-
coma Council in our institution.
We adopted a protocol for selection and preoperative
preparation of candidates for the treatment of tumors in the
hip and knee region with custom made megaendoprosthe-
ses. The protocol included surgical assessment of tumor
aggressiveness, biopsy and histopathological verification,
anatomical-mechanical determinants of the defect, the
status of soft tissues, exact CT evaluation of the pelvis, fe-
mur and tibia in order to design a custom made megaendo-
prosthesis and to plan the surgery. It was necessary to use a
modern minimally invasive surgical procedure, if possible.
After determination of the tumor surgical grade 
7–8, and
histopathological confirmation of diagnosis, special atten-
tion was paid to the exact evaluation of sizes and anatomi-
cal relations of pelvis, femur and tibia. All the patients
were examined with 3D Multi Slice Computerized Tomog-
raphy (3D MSCT). The dimensions of the bone tumor and
boundaries were estimated and resection borders were
planned. 3D MSCT reconstruction and precise computer-
generated model allowed the development of components
of megaendoprosthesis which fully corresponded to the
anatomy of a patient (Figure 1). That greatly facilitated the
surgical procedure, eliminated a number of concerns and
the need for additional versatility (it refered to an intraop-
erative need to add or subtract additional inserts on the size
of implants, which could certainly further weaken the
planned construction of endoprosthesis). In order to suc-
ceed, we made an exact preoperative evaluation of lesion
size, careful preoperative planning of the level and ade-
quate fabrication of a custom made megaendoprosthesis. In
order to ensure the safe margins, resection of significant
segments of healthy bone was sometimes required, which
could lead to abbreviations, reduced bone fixation and in-
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After the production and delivery of a custom made
megaendoprosthesis, in all the cases an additional preopera-
tive evaluation was carried out and surgery performed. All
surgical interventions were performed by the team of ortho-
pedic surgeons with extensive experience in the field of hip
and knee arthroplasty procedures. Besides the standard ap-
plication of reconstructive surgical techniques in the series,
we respected and practiced all principles of oncological sur-
gery (Figure 2).
Results
There were no intraoperative complications, neither
complications in the early postoperative period (a month af-
ter the surgery). All the patients were followed minimally 24
months postoperatively. Since the classic scoring systems,
routinely used for analysis of functional outcomes of hip and
knee arthroplasty lack specificity sufficient for tumor arthro-
plasty, we evaluated postoperative function with the Muscu-
Fig. 1 – Patient with chondrosarcoma of the distal femur
1) AP radiograph; 2) lateral radiograph; 3) and 4) 3D MSCT  model of the distal femur; 5) and 6) postoperative radiographs with the knee megaendoprosthesis
Fig. 2 –  1) Distal femur chondrosarcoma; 2) Resected distal femur; 3) and 4) Knee arthroplasty - custom made
megaendoprosthesisVolumen 68, Broj 1 VOJNOSANITETSKI PREGLED Strana 65
Barjaktarović R, et al. Vojnosanit Pregl 2011; 68(1): 62–67.
losceletal Tumor Society (MSTS) scoring system 
9–10. Nu-
merical values from 0 to 5 points were assigned for each of
the following 6 categories: pain, function, emotional accep-
tance, use of supports, walking ability and gait. These values
were added, and the functional score was presented as a per-
centage of the maximum possible score. The results were
graded according to the following scale: excellent – 75% to
100%; good – 70% to 74%; moderate – 60% to 69%; fair –
50% to 59% and poor – < 50% (Table 1). The overall sur-
vival of patients in the follow-up period was 100%
In the series there were seven knee megaendoprosthe-
ses, and one megaendoprosthesis of the hip. All patients un-
derwent wide resection of tumor and megaendoprosthetic re-
construction. The procedures were conducted during 2006
and 2007. In four cases an excellent result was achieved
(MSTS > 75, and mean MSTS functional score was 73.62%
which was slightly lower than in similar studies (Table 2).
Table 2
Comparison of our results with those of other authors
Study Number of
patients
MSTS functional
score (%)
Hiroyuki et al.
11 40 74
Schindler et al.
12 12 77
Wilkins et al. 
13 26 73
Khee Tan et al. 
14 19 78
Barjaktarović et al. (this
study)
87 3
MSTS – Musculosceletal Tumor Society
During the 24 months follow-up period there were no
lethal out come, although one male patient with chondrosar-
coma of proximal femur 18 month after the intervention de-
veloped pulmonary metastases; shortly after the 24-months
follow-up left our country and did not appear at the scheduled
control visits, and we had no information about the progress of
the disease or further treatment of the diagnosed metastatic
disease. At the same patient we recorded hip prosthesis dislo-
cation one month postoperatively, and after the reposition
there were no more reluxations. All the patients were regularly
checked up at the first month postoperatively and after three
months. They  were immediately allowed to walk postopera-
tively with the full weight bearing. In two patients during the
follow-up we noted a decrease of function and that resulted in
a significantly lower score at the final functional test. In one
case we identified the associated cardiac pathology, and in
other one obesity and low motivation for cooperation during
the rehabilitation and physiotherapy as main causes of low
scores. In one male patient with a giganticellular tumor of dis-
tal femur, after 6 months we registered an aseptic femoral
component loosening in the distal part. However, femoral stem
stability as a whole was not compromised, the patient was ad-
vised the restrictive mode of living, without denial of weight
bearing on to the operated leg. In further course loosening did
not advance at all. In one patient with femur osteosarcoma we
recorded slow wound healing without dehiscence and no need
for reinterventions.
Reconstructive procedures in the tretament of malignant
bone tumors have significantly higher incidence of compli-
cations compared to standard total joint arthroplasties 
15–16. In
tumor reconstructive surgery bone resections are usually
broad and necessarly affect a good portion of healthy tissue,
reducing the substrate for adequate fixation, and often are
followed by compromising effects of radio and chemother-
apy. This applies especially to slow wound healing and fre-
quent infections. In our series, we recorded one early super-
ficial wound infection. We isolated Staph. epidermidis. In-
fection was successfully treated with antibiotic therapy,
without additional surgical interventions.
Although we presented only light patients we are proud
to highlight the absence of the most common and certainly
the most difficult complications to resolve such as deep in-
fections, periprosthetic fractures, implant fractures, nerve
and vascular injuries.
Table 1
Musculoskeletol Tumor Society (MSTS) functional score in patients treated
by custom made tumor endoprosthesis
Patient (diagnosis, age and gender) MSTS funcional score* (%)
Chondro sarcoma partis distalis femoris sin, 57 yrs.
female 71
Chondrosarcoma partis distalis femoris dex, 65 yrs,
female 64
Tumor gigantocellulare partis distalis femoris sin, 25
yrs, male 83
Tumor gigantocellulare (Osteoclastoma) partis dista-
lis femoris sin, 51 yrs, male 75
Tu gigantocellulare partis distalis femoris dex, 33 yrs,
male 81
Osteosarcoma partis dist.fem. dex, 29 yrs, female 75
Osteosarcoma partis distalis femoris sin, 41 yrs, male 78
Chondrosarcoma partis proximalis femoris sin, 47
yrs, male 62
Average value of functional score 73.62
*excellent – 75% to 100%; good – 70% to 74%; moderate – 60% to 69%; fair – 50% to 59%; poor - < 50%.Strana 66 VOJNOSANITETSKI PREGLED Volumen 68, Broj 1
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Discussion
This retrospective study on a small sample certainly has
some weaknesses. But the basic weakness - the small sample
and relatively short duration of follow-up (24 months post-
operatively) are not significant for the purpose of the study,
since we wanted to examine the importance of proper selection
of patients with bone tumors and the impact of the megaendo-
prosthesis designed to snit an exact anatomical model on the
funcional outcome and complications associated with implants.
In order to check the reduction in the incidence of the most
common and most serious complications of tumor arthroplasty
period of 24 months is more than enough. The above compli-
cations are: infection, deep venous thrombosis, delayed wound
healing and dehiscence, dislocations, periprosthetic fractures,
fractures of implants and implant loosening, and they usually
occur in the first 6 months postoperatively.
Megaendoprosthetic reconstruction as a method for the
treatment of bone tumors has numerous advantages. It allows
immediate stability, and early rehabilitation with immediate
full weight bearing. We believe that the custom made endo-
prosthesis are far better than the prefabricated commercially
available modular implants. The absence of frequent compli-
cations related to endoprosthesis (implant fracture, polyeth-
ylene wear, dislocations, loosening of components) in our se-
ries highlights the importance of anatomical joint restitution
and adequate restoration of limb biomechanics in general.
There is no doubt that such effect can only be achieved by
custom made endoprosthesis produced upon the exact 3D
model of a patient's bone.
During the follow-up period there was no need for the
revision surgery, and we fand that it was certainly an impres-
sive result. We believe that the main reasons for the success
were valid indications for megaendoprosthetic reconstructive
surgery, studious preoperative preparation, precise and mod-
ern surgical technique and highly skilled surgical teams.
Biau et al. 
15 reported 91 patients with bone tumors in the re-
gion of the knee treated with endoprosthesis (not custom
made implants) and in 36 patients, endoprosthesis for various
reasons had to be removed. Gosheger et al. 
17 in a study on
250 patients treated with Mutars endoprosthesis (Implant-
cast, Buxtehude; not custom made implants) reported five-
year survival rate of 68.5%, with 8% of aseptic prosthesis
loosening. Mittermayer et al. 
18, in a study with 251 patient
treated with Kotz endoprosthesis (Howmedica, Rutherford,
New Jersey) reported 76% success after ten years, and
Malawer and Chou 
19 in the study with 82 patients reported
67% ten year-survival of megandoprosthesis.
We believe that it is not a small problem, as mentioned
above, of long-time research (longer than five years) binding
treatment for a specific type of an implant. It is a self-
limiting approach that often denies choice and possibly better
treatment for a patient. Orthopedic surgery and orthopedic
oncology in the past two decades have made substantial pro-
gress, mostly in the technology of implants and diagnostic
procedures. Neglect of fantastic technological evolution in
implant design, new materials, innovations in surgical proce-
dures and imaging techniques is unacceptable mistake that
can cost a lot, patients and doctors, as well.
A successfull megaendoprosthetic reconstruction re-
quires a perfectly coordinated teamwork of orthopedic sur-
geons, radiologists, oncologists, pathologists, physiatrists
and often other medical specialists, if necessary. That is why
we feel the need to emphasize that the orthopedic-oncology
megaendoprosthetic reconstruction is reserved for the highly
specialized institutions. They, in addition to experienced or-
thopedic surgeons, have the necessary resources – adequate
equipment, primarily modern imaging techniques (3D
MSCT, MRI), and competent specialists of different
branches of medicine.
Conclusion
Custom made megaendoprosthesis is the method of
choice in the treatment of bone tumors in the region of the
hip and knee. All procedures, presented in the paper, were
performed without complications during and immediately
after the surgery. During the follow up period not less than
24 months in all the cases we did not record any significant
complications. The greatest challenge - ensuring longevity of
a prosthesis, can be achieved not only by preventing com-
mon complications of artrhoplasty procedures but certainly
by introducting new methods for preoperative planning -
computer-assisted technique of measuring the referent ana-
tomical sizes and software solutions for the selection and de-
sign of custom-made components of endoprosthesis.
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